Literature DB >> 25074538

National Osteoporosis Society vitamin D guideline summary.

Terry J Aspray1, Claire Bowring2, William Fraser3, Neil Gittoes4, M Kassim Javaid5, Helen Macdonald6, Sanjeev Patel7, Peter Selby8, Nuttan Tanna9, Roger M Francis10.   

Abstract

The National Osteoporosis Society (NOS) published its document, Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management, in 2013 as a practical clinical guideline on the management of vitamin D deficiency in adult patients with, or at risk of developing, bone disease. There has been no clear consensus in the UK on vitamin D deficiency its assessment and treatment, and clinical practice is inconsistent. This guideline is aimed at clinicians, including doctors, nurses and dieticians. It recommends the measurement of serum 25 (OH) vitamin D (25OHD) to estimate vitamin D status in the following clinical scenarios: bone diseases that may be improved with vitamin D treatment; bone diseases, prior to specific treatment where correcting vitamin D deficiency is appropriate; musculoskeletal symptoms that could be attributed to vitamin D deficiency. The guideline also states that routine vitamin D testing is unnecessary where vitamin D supplementation with an oral antiresorptive treatment is already planned and sets the following serum 25OHD thresholds: <30 nmol/l is deficient; 30-50 nmol/l may be inadequate in some people; >50 nmol/l is sufficient for almost the whole population. For treatment, oral vitamin D3 is recommended with fixed loading doses of oral vitamin D3 followed by regular maintenance therapy when rapid correction of vitamin D deficiency is required, although loading doses are not necessary where correction of deficiency is less urgent or when co-prescribing with an oral antiresorptive agent. For monitoring, serum calcium (adjusted for albumin) should be checked 1 month after completing a loading regimen, or after starting vitamin D supplementation, in case primary hyperparathyroidism has been unmasked. However, routine monitoring of serum 25OHD is generally unnecessary but may be appropriate in patients with symptomatic vitamin D deficiency or malabsorption and where poor compliance with medication is suspected. The guideline focuses on bone health as, although there are numerous putative effects of vitamin D on immunity modulation, cancer prevention and the risks of cardiovascular disease and multiple sclerosis, there remains considerable debate about the evaluation of extraskeletal factors and optimal vitamin D status in these circumstances.
© The Author 2014. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  muscle and vitamin D; osteomalacia; vitamin D deficiency; vitamin D deficiency threshold; vitamin D testing older people

Mesh:

Substances:

Year:  2014        PMID: 25074538     DOI: 10.1093/ageing/afu093

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  45 in total

Review 1.  Bone Health following Bariatric Surgery: Implications for Management Strategies to Attenuate Bone Loss.

Authors:  Tair Ben-Porat; Ram Elazary; Shiri Sherf-Dagan; Ariela Goldenshluger; Ronit Brodie; Yoav Mintz; Ram Weiss
Journal:  Adv Nutr       Date:  2018-03-01       Impact factor: 8.701

Review 2.  Does vitamin D play a role in autoimmune endocrine disorders? A proof of concept.

Authors:  Barbara Altieri; Giovanna Muscogiuri; Luigi Barrea; Chantal Mathieu; Carla V Vallone; Luca Mascitelli; Giorgia Bizzaro; Vincenzo M Altieri; Giacomo Tirabassi; Giancarlo Balercia; Silvia Savastano; Nicola Bizzaro; Cristina L Ronchi; Annamaria Colao; Alfredo Pontecorvi; Silvia Della Casa
Journal:  Rev Endocr Metab Disord       Date:  2017-09       Impact factor: 6.514

3.  Vitamin D status, hypertension and ischemic stroke: a clinical perspective.

Authors:  V Majumdar; P Prabhakar; G B Kulkarni; R Christopher
Journal:  J Hum Hypertens       Date:  2015-03-26       Impact factor: 3.012

4.  Serum 25-hydroxyvitamin D cutoffs for functional bone measures in postmenopausal osteoporosis.

Authors:  D Y Lee; J H Jee; Y Y Cho; J Y Jang; T Y Yu; T H Kim; Y J Hong; W-J Hong; S-M Jin; K Y Hur; J H Kim; S W Kim; J H Chung; M K Lee; Y-K Min
Journal:  Osteoporos Int       Date:  2017-02-10       Impact factor: 4.507

5.  Hypovitaminosis D and fat mass in healthy older people.

Authors:  N Veronese; C Trevisan; S Carraro; S Sarti; B M Zanforlini; M De Rui; A Coin; E Manzato; G Sergi
Journal:  Eur J Clin Nutr       Date:  2016-06-01       Impact factor: 4.016

6.  Vitamin D supplementation in nursing home patients: randomized controlled trial of standard daily dose versus individualized loading dose regimen.

Authors:  Hugo Wijnen; Dayenne Salemink; Lian Roovers; Diana Taekema; Hans de Boer
Journal:  Drugs Aging       Date:  2015-05       Impact factor: 3.923

Review 7.  Vitamin D Metabolism and Guidelines for Vitamin D Supplementation.

Authors:  Indra Ramasamy
Journal:  Clin Biochem Rev       Date:  2020-12

8.  Vitamin D supplementation has no effects on progression of motor dysfunction in amyotrophic lateral sclerosis (ALS).

Authors:  Francesca Trojsi; Mattia Siciliano; Carla Passaniti; Alvino Bisecco; Antonio Russo; Luigi Lavorgna; Sabrina Esposito; Dario Ricciardi; Maria Rosaria Monsurrò; Gioacchino Tedeschi; Gabriella Santangelo
Journal:  Eur J Clin Nutr       Date:  2019-06-13       Impact factor: 4.016

Review 9.  Maternal vitamin D supplementation during pregnancy.

Authors:  Elizabeth M Curtis; Rebecca J Moon; Nicholas C Harvey; Cyrus Cooper
Journal:  Br Med Bull       Date:  2018-06-01       Impact factor: 4.291

Review 10.  How can the orthopedic surgeon ensure optimal vitamin D status in patients operated for an osteoporotic fracture?

Authors:  T Chevalley; M L Brandi; E Cavalier; N C Harvey; G Iolascon; C Cooper; D Hannouche; J-F Kaux; A Kurth; S Maggi; G Maier; K Papavasiliou; N Al-Daghri; M Sosa-Henríquez; N Suhm; U Tarantino; J-Y Reginster; R Rizzoli
Journal:  Osteoporos Int       Date:  2021-05-20       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.